dafabet online betting

Learn more about Tris’ technologies here.

Kye Pharma

dafabet live casinoKye Pharma was Tris Pharma’s first ex-U.S. partner for our approved ADHD portfolio, bringing our ADHD medicines to patients in Canada.

Neuraxpharm

Neuraxpharm licensed the rights to develop and commercialize our FDA-approved Quillivant XR and Quillichew ER in 40+ European countries.

Pediatrix Therapeutics

We partnered with Pediatrix Therapeutics to bring our FDA-approved ADHD medicines, as well as an investigational ADHD therapy, to patients in China.

Perrigo Co.

Perrigo has a been a commercial partner since 2012.

Perigon Pharmacy

We partnered with Perigon dafabet sports bettingPharmacy 360 to enhance accessibility, affordability and adherence via a digital pharmacy for patients.

Braingaze

We licensed the rights to develop and commercialize Braingaze’s first-in-class, AI-enhanced digital ADHD diagnostic platform in the United States and Canada.

Interested in collaborating with Tris? Whether it’s a program you want to out-license, or an ex-U.S. or Tris-technology partnership, we’d love to hear from you!

This form is not intended for use in reporting adverse events related to Tris medicines. You may report such events by calling dafabet casino app1-732-940-0358 (U.S. only). If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. The FDA has established a reporting service known as MedWatch, where healthcare professionals and consumers can report serious problems they suspect may be associated with the drugs and medical devices they prescribe, dispense or use. Visit MedWatch or call 1-800-FDA-1088.

Tris Pharma is committed to addressing the needs of patients globally through strategic partnerships and anticipated regulatory filings in multiple ex-U.S. countries.